Mesenchymal stromal cells and toll-like receptor priming: A critical review

Immune Network

Volumn 17, Issue 2, 2017, Pages 89-102

  Najar, Mehdi ^a   Krayem, Mohammad ^a   Meuleman, Nathalie ^a   Bron, Dominique ^a   Lagneaux, Laurence ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Hematopoietic support; Immunomodulation; MSCs; Multilineage potential; Phenotype; Priming; TLR

Indexed keywords

TOLL LIKE RECEPTOR;

BIOLOGICAL FUNCTIONS; HEMATOPOIETIC CELL; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION SENSITIVITY; MESENCHYMAL STROMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 85020124278     PISSN: 15982629     EISSN: 20926685     Source Type: Journal    
DOI: 10.4110/in.2017.17.2.89     Document Type: Review

References (100)

1. Fayyad-Kazan, M., H. Fayyad-Kazan, L. Lagneaux, and M. Najar. 2016. The potential of mesenchymal stromal cells in immunotherapy. Immunotherapy 8: 839-842.
2. Hass, R., C. Kasper, S. Bohm, and R. Jacobs. 2011. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun. Signal 9: 12.
3. El, O. R., J. Beroud, J. F. Stoltz, P. Menu, E. Velot, and V. Decot. 2014. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies? Tissue Eng. Part B Rev. 20: 523-544.
4. Owen, M., and A. J. Friedenstein. 1988. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found. Symp. 136: 42-60.
5. Caplan, A. I., and D. Correa. 2011. The MSC: an injury drugstore. Cell Stem Cell 9: 11-15.
6. Horwitz, E. M., B. K. Le, M. Dominici, I. Mueller, I. Slaper-Cortenbach, F. C. Marini, R. J. Deans, D. S. Krause, and A. Keating. 2005. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7: 393-395.
7. Dominici, M., B. K. Le, I. Mueller, I. Slaper-Cortenbach, F. Marini, D. Krause, R. Deans, A. Keating, D. Prockop, and E. Horwitz. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
8. Pittenger, M. F., A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. Mosca, M. A. Moorman, D. W. Simonetti, S. Craig, and D. R. Marshak. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
9. Anthony, B. A., and D. C. Link. 2014. Regulation of hematopoietic stem cells by bone marrow stromal cells. Trends Immunol. 35: 32-37.
10. Fajardo-Orduna, G. R., H. Mayani, and J. J. Montesinos. 2015. Hematopoietic support capacity of mesenchymal stem cells: Biology and clinical potential. Arch. Med. Res. 46: 589-596.
11. Frenette, P. S., S. Pinho, D. Lucas, and C. Scheiermann. 2013. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu. Rev. Immunol. 31: 285-316.
12. Battiwalla, M., and P. Hematti. 2009. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy 11: 503-515.
13. Baksh, D., R. Yao, and R. S. Tuan. 2007. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 25: 1384-1392.
14. De Ugarte, D. A., K. Morizono, A. Elbarbary, Z. Alfonso, P. A. Zuk, M. Zhu, J. L. Dragoo, P. Ashjian, B. Thomas, P. Benhaim, I. Chen, J. Fraser, and M. H. Hedrick. 2003. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 174: 101-109.
15. Kariminekoo, S., A. Movassaghpour, A. Rahimzadeh, M. Talebi, K. Shamsasenjan, and A. Akbarzadeh. 2016. Implications of mesenchymal stem cells in regenerative medicine. Artif. Cells Nanomed. Biotechnol. 44: 749-757.
16. Najar, M., G. Raicevic, E. Crompot, H. Fayyad-Kazan, D. Bron, M. Toungouz, and L. Lagneaux. 2016. The immunomodulatory potential of mesenchymal stromal cells: A story of a regulatory network. J. Immunother. 39: 45-59.
17. Najar, M., G. Raicevic, H. Fayyad-Kazan, D. Bron, M. Toungouz, and L. Lagneaux. 2016. Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells. Cytotherapy 18: 160-171.
18. Murphy, M. B., K. Moncivais, and A. I. Caplan. 2013. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp. Mol. Med. 45: e54.
19. Uccelli, A., V. Pistoia, and L. Moretta. 2007. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 28: 219-226.
20. Reddy, P., and J. L. Ferrara. 2003. Immunobiology of acute graft-versus-host disease. Blood Rev. 17: 187-194.
21. Hwa, C. H., Y. C. Bae, and J. S. Jung. 2006. Role of toll-like receptors on human adipose-derived stromal cells. Stem Cells 24: 2744-2752.
22. Pevsner-Fischer, M., and D. Zipori. 2009. Environmental Signals Regulating Mesenchymal Progenitor Cell Growth and Differentiation. In Regulatory Networks in Stem Cells. Stem Cell Biology and Regenerative Medicine V. K. R. Ms. MPhil, and M. C. Vemuri, eds. Humana Press. 175-184.
23. Janeway, C. A. Jr., and R. Medzhitov. 2002. Innate immune recognition. Annu. Rev. Immunol. 20: 197-216.
24. Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11: 373-384.
25. Medzhitov, R. 2007. Recognition of microorganisms and activation of the immune response. Nature 449: 819-826.
26. Kumar, H., T. Kawai, and S. Akira. 2011. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30: 16-34.
27. Rich, T. 2007. Toll and Toll-Like Receptors:: An Immunologic Perspective. Springer Science & Business Media. page 25-26.
28. kashi-Takamura, S., and K. Miyake. 2008. TLR accessory molecules. Curr. Opin. Immunol. 20: 420-425.
29. Jin, M. S., S. E. Kim, J. Y. Heo, M. E. Lee, H. M. Kim, S. G. Paik, H. Lee, and J. O. Lee. 2007. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130: 1071-1082.
30. Kang, J. Y., X. Nan, M. S. Jin, S. J. Youn, Y. H. Ryu, S. Mah, S. H. Han, H. Lee, S. G. Paik, and J. O. Lee. 2009. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31: 873-884.
31. Kumar, H., T. Kawai, and S. Akira. 2009. Pathogen recognition in the innate immune response. Biochem. J. 420: 1-16.
32. Takeuchi, O., and S. Akira. 2010. Pattern recognition receptors and inflammation. Cell 140: 805-820.
33. Guan, Y., D. R. Ranoa, S. Jiang, S. K. Mutha, X. Li, J. Baudry, and R. I. Tapping. 2010. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J. Immunol. 184: 5094-5103.
34. Zanin-Zhorov, A., and I. R. Cohen. 2013. Signaling via TLR2 and TLR4 directly down-regulates T cell effector functions: The regulatory face of danger signals. Front. Immunol. 4: 211.
35. Huang, Y., and Z. Chen. 2016. Inflammatory bowel disease related innate immunity and adaptive immunity. Am. J. Transl. Res. 8: 2490-2497.
36. Ishihara, S., M. A. Rumi, C. F. Ortega-Cava, H. Kazumori, Y. Kadowaki, N. Ishimura, and Y. Kinoshita. 2006. Therapeutic targeting of toll-like receptors in gastrointestinal inflammation. Curr. Pharm. Des 12: 4215-4228.
37. Yamamoto-Furusho, J. K., and D. K. Podolsky. 2007. Innate immunity in inflammatory bowel disease. World J. Gastroenterol. 13: 5577-5580.
38. Fuenzalida, P., M. Kurte, C. Fernandez-O'ryan, C. Ibanez, M. Gauthier-Abeliuk, A. M. Vega-Letter, P. Gonzalez, C. Irarrazabal, N. Quezada, F. Figueroa, and F. Carrion. 2016. Toll-like receptor 3 pre-conditioning increases the therapeutic efficacy of umbilical cord mesenchymal stromal cells in a dextran sulfate sodium-induced colitis model. Cytotherapy 18: 630-641.
39. Parker, L. C., L. R. Prince, and I. Sabroe. 2007. Translational mini-review series on Toll-like receptors: networks regulated by Toll-like receptors mediate innate and adaptive immunity. Clin. Exp. Immunol. 147: 199-207.
40. Krishnan, J., K. Selvarajoo, M. Tsuchiya, G. Lee, and S. Choi. 2007. Toll-like receptor signal transduction. Exp. Mol. Med. 39: 421-438.
41. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995.
42. Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1: 135-145.
43. Vaknin, I., L. Blinder, L. Wang, R. Gazit, E. Shapira, O. Genina, M. Pines, E. Pikarsky, and M. Baniyash. 2008. A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression. Blood 111: 1437-1447.
44. Hornef, M. W., and C. Bogdan. 2005. The role of epithelial Toll-like receptor expression in host defense and microbial tolerance. J. Endotoxin Res. 11: 124-128.
45. Yang, X., D. Coriolan, V. Murthy, K. Schultz, D. T. Golenbock, and D. Beasley. 2005. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am. J. Physiol. Heart Circ. Physiol. 289: H1069-H1076.
46. Pevsner-Fischer, M., V. Morad, M. Cohen-Sfady, L. Rousso-Noori, A. Zanin-Zhorov, S. Cohen, I. R. Cohen, and D. Zipori. 2007. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109: 1422-1432.
47. Lombardo, E., O. DelaRosa, P. Mancheno-Corvo, R. Menta, C. Ramirez, and D. Buscher. 2009. Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. Tissue Eng. Part A 15: 1579-1589.
48. Tomchuck, S. L., K. J. Zwezdaryk, S. B. Coffelt, R. S. Waterman, E. S. Danka, and A. B. Scandurro. 2008. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26: 99-107.
49. Opitz, C. A., U. M. Litzenburger, C. Lutz, T. V. Lanz, I. Tritschler, A. Koppel, E. Tolosa, M. Hoberg, J. Anderl, W. K. Aicher, M. Weller, W. Wick, and M. Platten. 2009. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27: 909-919.
50. Krampera, M., S. Sartoris, F. Liotta, A. Pasini, R. Angeli, L. Cosmi, A. Andreini, F. Mosna, B. Bonetti, E. Rebellato, M. G. Testi, F. Frosali, G. Pizzolo, G. Tridente, E. Maggi, S. Romagnani, and F. Annunziato. 2007. Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. Stem Cells Dev. 16: 797-810.
51. Romieu-Mourez, R., M. Francois, M. N. Boivin, M. Bouchentouf, D. E. Spaner, and J. Galipeau. 2009. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J. Immunol. 182: 7963-7973.
52. + cells. Exp. Cell Res. 318: 196-206.
53. Raicevic, G., R. Rouas, M. Najar, P. Stordeur, H. I. Boufker, D. Bron, P. Martiat, M. Goldman, M. T. Nevessignsky, and L. Lagneaux. 2010. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum. Immunol. 71: 235-244.
54. Raicevic, G., M. Najar, B. Stamatopoulos, B. C. De, N. Meuleman, D. Bron, M. Toungouz, and L. Lagneaux. 2011. The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell. Immunol. 270: 207-216.
55. van den Berk, L. C., B. J. Jansen, K. G. Siebers-Vermeulen, M. G. Netea, T. Latuhihin, S. Bergevoet, R. A. Raymakers, G. Kogler, C. C. Figdor, G. J. Adema, and R. Torensma. 2009. Toll-like receptor triggering in cord blood mesenchymal stem cells. J. Cell. Mol. Med. 13: 3415-3426.
56. Sato, B. L., E. S. Collier, S. A. Vermudez, A. D. Junker, and C. E. Kendal-Wright. 2016. Human amnion mesenchymal cells are pro-inflammatory when activated by the Toll-like receptor 2/6 ligand, macrophage-activating lipoprotein-2. Placenta 44: 69-79.
57. Tomic, S., J. Djokic, S. Vasilijic, D. Vucevic, V. Todorovic, G. Supic, and M. Colic. 2011. Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by toll-like receptor agonists. Stem Cells Dev. 20: 695-708.
58. Cho, H. H., K. K. Shin, Y. J. Kim, J. S. Song, J. M. Kim, Y. C. Bae, C. D. Kim, and J. S. Jung. 2010. NF-kappaB activation stimulates osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue by increasing TAZ expression. J. Cell. Physiol. 223: 168-177.
59. Chen, G. Y., H. C. Shiah, H. J. Su, C. Y. Chen, Y. J. Chuang, W. H. Lo, J. L. Huang, C. K. Chuang, S. M. Hwang, and Y. C. Hu. 2009. Baculovirus transduction of mesenchymal stem cells triggers the toll-like receptor 3 pathway. J. Virol. 83: 10548-10556.
60. Sung, D. K., Y. S. Chang, S. I. Sung, H. S. Yoo, S. Y. Ahn, and W. S. Park. 2016. Antibacterial effect of mesenchymal stem cells against Escherichia coli is mediated by secretion of beta- defensin- 2 via toll- like receptor 4 signalling. Cell. Microbiol. 18: 424-436.
61. Fawzy-El-Sayed, K., M. Mekhemar, S. dam-Klages, D. Kabelitz, and C. Dorfer. 2016. TlR expression profile of human gingival margin-derived stem progenitor cells. Med. Oral Patol. Oral Cir. Bucal. 21: e30-e38.
62. DelaRosa, O., and E. Lombardo. 2010. Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. Mediators Inflamm. 2010: 865601.
63. Kota, D. J., B. DiCarlo, R. A. Hetz, P. Smith, C. S. Cox, Jr., and S. D. Olson. 2014. Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms. Sci. Rep. 4: 4565.
64. Liotta, F., R. Angeli, L. Cosmi, L. Fili, C. Manuelli, F. Frosali, B. Mazzinghi, L. Maggi, A. Pasini, V. Lisi, V. Santarlasci, L. Consoloni, M. L. Angelotti, P. Romagnani, P. Parronchi, M. Krampera, E. Maggi, S. Romagnani, and F. Annunziato. 2008. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26: 279-289.
65. Waterman, R. S., S. L. Tomchuck, S. L. Henkle, and A. M. Betancourt. 2010. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 5: e10088.
66. Zhang, L., D. Liu, D. Pu, Y. Wang, L. Li, Y. He, Y. Li, L. Li, Z. Qiu, S. Zhao, and W. Li. 2015. The role of Toll-like receptor 3 and 4 in regulating the function of mesenchymal stem cells isolated from umbilical cord. Int. J. Mol. Med. 35: 1003-1010.
67. Ryu, J. H., M. Park, B. K. Kim, K. H. Ryu, and S. Y. Woo. 2015. Tonsil-derived mesenchymal stromal cells produce CXCR2-binding chemokines and acquire follicular dendritic cell-like phenotypes under TLR3 stimulation. Cytokine 73: 225-235.
68. Caplan, A. I., and J. E. Dennis. 2006. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 98: 1076-1084.
69. Kim, H. S., T. H. Shin, S. R. Yang, M. S. Seo, D. J. Kim, S. K. Kang, J. H. Park, and K. S. Kang. 2010. Implication of NOD1 and NOD2 for the differentiation of multipotent mesenchymal stem cells derived from human umbilical cord blood. PLoS One 5: e15369.
70. He, X., H. Wang, T. Jin, Y. Xu, L. Mei, and J. Yang. 2016. TLR4 activation promotes bone marrow MSC proliferation and osteogenic differentiation via Wnt3a and Wnt5a signaling. PLoS One 11: e0149876.
71. Qi, C., X. Xiaofeng, and W. Xiaoguang. 2014. Effects of toll-like receptors 3 and 4 in the osteogenesis of stem cells. Stem Cells Int. 2014: 917168.
72. Zhang, W. Q., S. H. Huang, X. Huang, J. H. Li, P. Ye, J. Xu, P. Z. Zheng, H. Y. Shen, and J. R. Huang. 2016. Regulation of human mesenchymal stem cell differentiation by TREM-2. Hum. Immunol. 77: 476-482.
73. Mo, I. F., K. H. Yip, W. K. Chan, H. K. Law, Y. L. Lau, and G. C. Chan. 2008. Prolonged exposure to bacterial toxins downregulated expression of toll-like receptors in mesenchymal stromal cell-derived osteoprogenitors. BMC Cell Biol. 9: 52.
74. Chen, X., Z. Y. Zhang, H. Zhou, and G. W. Zhou. 2014. Characterization of mesenchymal stem cells under the stimulation of Toll-like receptor agonists. Dev. Growth Differ. 56: 233-244.
75. Raicevic, G., M. Najar, K. Pieters, B. C. De, N. Meuleman, D. Bron, M. Toungouz, and L. Lagneaux. 2012. Inflammation and Toll-like receptor ligation differentially affect the osteogenic potential of human mesenchymal stromal cells depending on their tissue origin. Tissue Eng. Part A 18: 1410-1418.
76. Valtieri, M., and A. Sorrentino. 2008. The mesenchymal stromal cell contribution to homeostasis. J. Cell. Physiol. 217: 296-300.
77. Mendez-Ferrer, S., T. V. Michurina, F. Ferraro, A. R. Mazloom, B. D. Macarthur, S. A. Lira, D. T. Scadden, A. Ma'ayan, G. N. Enikolopov, and P. S. Frenette. 2010. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466: 829-834.
78. Shi, C., T. Jia, S. Mendez-Ferrer, T. M. Hohl, N. V. Serbina, L. Lipuma, I. Leiner, M. O. Li, P. S. Frenette, and E. G. Pamer. 2011. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity 34: 590-601.
79. Ziegler, P., S. Boettcher, H. Takizawa, M. G. Manz, and T. H. Brummendorf. 2016. LPS-stimulated human bone marrow stroma cells support myeloid cell development and progenitor cell maintenance. Ann. Hematol. 95: 173-178.
80. Iwamura, C., N. Bouladoux, Y. Belkaid, A. Sher, and D. Jankovic. 2017. Sensing of the microbiota by NOD1 in mesenchymal stromal cells regulates murine hematopoiesis. Blood 129: 171-176.
81. Bernardo, M. E. and W. E. Fibbe. 2013. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13: 392-402.
82. Hwang, S. H., H. K. Cho, S. H. Park, W. Lee, H. J. Lee, D. C. Lee, J. H. Oh, S. H. Park, T. G. Kim, H. J. Sohn, J. M. Kang, and S. W. Kim. 2014. Toll like receptor 3 & 4 responses of human turbinate derived mesenchymal stem cells: stimulation by double stranded RNA and lipopolysaccharide. PLoS One 9: e101558.
83. Tomchuck, S. L., S. L. Henkle, S. B. Coffelt, and A. M. Betancourt. 2012. Toll-like receptor 3 and suppressor of cytokine signaling proteins regulate CXCR4 and CXCR7 expression in bone marrow-derived human multipotent stromal cells. PLoS One 7: e39592.
84. Najar, M., G. Raicevic, H. Fayyad-Kazan, B. C. De, D. Bron, M. Toungouz, and L. Lagneaux. 2013. Impact of different mesenchymal stromal cell types on T-cell activation, proliferation and migration. Int. Immunopharmacol. 15: 693-702.
85. Dumitru, C. A., H. Hemeda, M. Jakob, S. Lang, and S. Brandau. 2014. Stimulation of mesenchymal stromal cells (MSCs) via TLR3 reveals a novel mechanism of autocrine priming. FASEB J. 28: 3856-3866.
86. Yan, H., M. Wu, Y. Yuan, Z. Z. Wang, H. Jiang, and T. Chen. 2014. Priming of Toll-like receptor 4 pathway in mesenchymal stem cells increases expression of B cell activating factor. Biochem. Biophys. Res. Commun. 448: 212-217.
87. Levin, S., M. Pevsner-Fischer, S. Kagan, H. Lifshitz, A. Weinstock, D. Gataulin, G. Friedlander, and D. Zipori. 2014. Divergent levels of LBP and TGFbeta1 in murine MSCs lead to heterogenic response to TLR and proinflammatory cytokine activation. Stem Cell Rev. 10: 376-388.
88. Lei, J., Z. Wang, D. Hui, W. Yu, D. Zhou, W. Xia, C. Chen, Q. Zhang, Z. Wang, Q. Zhang, and A. P. Xiang. 2011. Ligation of TLR2 and TLR4 on murine bone marrow-derived mesenchymal stem cells triggers differential effects on their immunosuppressive activity. Cell Immunol. 271: 147-156.
89. Weinstock, A., M. Pevsner-Fischer, Z. Porat, M. Selitrennik, and D. Zipori. 2015. Cultured mesenchymal stem cells stimulate an immune response by providing immune cells with Toll-like receptor 2 ligand. Stem Cell Rev. 11: 826-840.
90. Rashedi, I., A. Gomez-Aristizabal, X. H. Wang, S. Viswanathan, and A. Keating. 2017. TLR3 or TLR4 activation enhances mesenchymal stromal cell-mediated Treg induction via notch signaling. Stem Cells 35: 265-275.
91. Wang, X., Y. Zhu, B. Xu, J. Wang, and X. Liu. 2016. Identification of TLR2 and TLR4induced microRNAs in human mesenchymal stem cells and their possible roles in regulating TLR signals. Mol. Med. Rep. 13: 4969-4980.
92. Zhao, X., D. Liu, W. Gong, G. Zhao, L. Liu, L. Yang, and Y. Hou. 2014. The toll-like receptor 3 ligand, poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143. Stem Cells 32: 521-533.
93. Sioud, M., A. Mobergslien, A. Boudabous, and Y. Floisand. 2010. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand. J. Immunol. 71: 267-274.
94. Gieseke, F., A. Kruchen, N. Tzaribachev, F. Bentzien, M. Dominici, and I. Muller. 2013. Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation. Eur. J. Immunol. 43: 2741-2749.
95. Cho, K. A., M. Park, Y. H. Kim, K. H. Ryu, and S. Y. Woo. 2017. Poly I:C primes the suppressive function of human palatine tonsil-derived MSCs against Th17 differentiation by increasing PD-L1 expression. Immunobiology 222: 394-398.
96. Qiu, Y., J. Guo, R. Mao, K. Chao, B. L. Chen, Y. He, Z. R. Zeng, S. H. Zhang, and M. H. Chen. 2016. TLR3 preconditioning enhances the therapeutic efficacy of umbilical cord mesenchymal stem cells in TNBS-induced colitis via the TLR3-Jagged-1-Notch-1 pathway. Mucosal. Immunol. doi: 10.1038/mi.2016.78.
97. Goriely, S., M. F. Neurath, and M. Goldman. 2008. How microorganisms tip the balance between interleukin-12 family members. Nat. Rev. Immunol. 8: 81-86.
98. Cassatella, M. A., F. Mosna, A. Micheletti, V. Lisi, N. Tamassia, C. Cont, F. Calzetti, M. Pelletier, G. Pizzolo, and M. Krampera. 2011. Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells 29: 1001-1011.
99. Giuliani, M., A. naceur-Griscelli, A. Nanbakhsh, N. Oudrhiri, S. Chouaib, B. Azzarone, A. Durrbach, and J. J. Lataillade. 2014. TLR ligands stimulation protects MSC from NK killing. Stem Cells 32: 290-300.
100. Lu, Y., J. Liu, Y. Liu, Y. Qin, Q. Luo, Q. Wang, and H. Duan. 2015. TLR4 plays a crucial role in MSC-induced inhibition of NK cell function. Biochem. Biophys. Res. Commun. 464: 541-547.